vTv Therapeutics (VTVT) Share-based Compensation (2015 - 2026)

vTv Therapeutics has disclosed Share-based Compensation across 12 years of filings, most recently posting $1.7 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 85.7% year-over-year to $1.7 million; the TTM figure through Jun 2026 stood at $5.1 million (up 50.45% YoY), while the FY2025 annual figure was $3.8 million, up 36.92% from the prior year.
• Share-based Compensation came in at $1.7 million for Q2 2026 at vTv Therapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.7 million in Q1 2022 to a low of $167000.0 in Q2 2022.
• Average Share-based Compensation over 5 years is $985741.2, with a median of $819000.0 recorded in 2024.
• Year-over-year, Share-based Compensation tumbled 96.27% in 2022 and jumped 269.55% in 2025.
• Over 5 years, Share-based Compensation stood at $291000.0 in 2022, then soared by 38.49% to $403000.0 in 2023, then soared by 104.71% to $825000.0 in 2024, then gained by 24.24% to $1.0 million in 2025, then surged by 68.49% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.7 million in Q2 2026, $1.4 million in Q1 2026, and $1.0 million in Q4 2025.